| Product vision |
- Uncomplicated malaria treatment and resistance management
|
| MoA |
|
| Key features |
- Fast killing in vitro and in vivo
- No resistant mutants identified
- Low predicted dose (100 mg) and 200 h predicted half-life
|
| Challenges |
- Human PK prediction for low clearance compounds
- Synthetic route: Palladium used in two chemical steps
|
| Status |
- Metabolite identification ongoing to confirm human PK prediction
- Photosafety study ongoing
|
| Next milestone |
- Completion of Good Laboratory Practice (GLP) toxicology programme
|
| Previously |
|
| MMV Project Director |
|
